


Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in My Watchlist
Most Trending
INSM
Insmed
$166.55
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Investors confidence is positive
Technical Indicators

Pattern Watch

Oversold
INSM Price Performance
$198.76 (-16.21%)
$135.59 (+22.83%)
$105.18 (+58.35%)
$69.86 (+138.41%)
INSM has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

INSM overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
INSM Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
INSM Street Sentiment is bullish and have positive views on the near-term outlook
Average key support and resistance price levels
SNY
47.99
-0.31%
XOMA
24.90
-1.43%
REGN
748.71
-0.14%
MRK
100.69
+1.49%
MLTX
13.26
-4.95%
What is INSM current stock price?
What are INSM stock strengths?
What is INSM Risk Level?
What is INSM market cap and volume?
What is INSM current Stock IQ?
Should I buy INSM stock right now?
Is INSM a Strong Buy right now?
What does a 'Strong Buy' rating mean for INSM?
What does a 'Strong Sell' rating mean for INSM?
What factors influence INSM's Stock IQ?
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
INSM
Insmed
Current Price
$166.55
Stock Insights
Strengths

Upgraded on attractively valued

Earnings are forecast to grow

Outperform the market

Investors confidence is positive
Technical Indicators

Pattern Watch

Oversold
Linked to INSM
SNY
47.99
-0.31%
XOMA
24.90
-1.43%
REGN
748.71
-0.14%
MRK
100.69
+1.49%
MLTX
13.26
-4.95%

INSM Price Performance
$198.76 (-16.21%)
$135.59 (+22.83%)
$105.18 (+58.35%)
$69.86 (+138.41%)
INSM Analysts Opinion
INSM Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings

Below analyst estimate

Earnings decline YoY
Rating
Rating

Upgraded on attractively valued
Momentum
Momentum

Price value has negative momentum
Activity
Activity

Investors confidence is positive
Future
Future

Earnings are forecast to grow

Outperform the market
![]()
INSM Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction and growth potential
INSM Street Sentiment is bullish and have positive views on the near-term outlook
INSM has Fair risk level based on volatility, sector strength, volume, investor confidence and outlook.
Click here to check what is your level of risk
Risks Indicators

Beta greater than 1.0

Average key support and resistance price levels
INSM Stock IQ
INSM Latest Analysis
Noteworthy Thursday Option Activity: INSM MDB HEI. Looking at options trading activity among components of the Russell 3000 index there is noteworthy activity today in Insmed Inc (Symbol: INSM) where a total volume of 13421 contracts has been traded thus far today a contract volume which is representative of approximately 1.
Thu Dec 18, 2025
Why Is Insmed Stock Falling Thursday?. INSM) stock plunged on Thursday.The company released data from the Phase 2b BiRCh study of brensocatib in patients with chronic rhinosinusitis .The trial did not meet its primary or secondary efficacy endpoints in either the 10 mg or .Brensocatib was well tolerated with no new safety signals identified including in the 40 mg arm which is the highest dose Insmed has studied to date.Insmed has discontinued its development program of brensocatib in CRSsNP effe
Thu Dec 18, 2025
Insmed is Now Oversold (INSM). Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which me
Thu Dec 18, 2025
INSM Stock Plummets on Sinus Study Failure Adds New Pipeline Asset. Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study while the company adds a new monoclonal antibody asset to expand its pipeline.
Thu Dec 18, 2025
Top 3 Health Care Stocks Youll Regret Missing This Quarter. The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.The RSI is a momentum indicator which compares a stock’.s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’.s price action it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is bel
Thu Dec 18, 2025
Insmed Plunges As Phase 2b BiRCh Data Disappoint. Acquires Phase 2 Ready Monoclonal Antibody . (RTTNews) - Insmed Inc. (INSM) announced that its Phase 2b BiRCh study of brensocatib for chronic rhinosinusitis without nasal polyps did not meet its primary or secondary efficacy endpoints in both the 10 mg and 40 mg treatment arms.
Thu Dec 18, 2025
The Worst-Case Scenario — Why Insmed Just Reversed Its 181% Six-Month Sprint. Insmed stock crumbled late Wednesday after the highly rated biotech company scrapped one of its brensocatib studies.The post The '.Worst-Case Scenario'. — Why Insmed Just Reversed Its 181% Six-Month Sprint appeared first on Investor'.s Business Daily.
Thu Dec 18, 2025
Insmed drops as it abandons brensocatib in rhinosinusitis.
Wed Dec 17, 2025
Insmed stock plunges after failed Phase 2b study in CRSsNP.
Wed Dec 17, 2025
Wells Fargo Maintains Insmed (INSM) Overweight Recommendation. Fintel reports that on December 16 2025 Wells Fargo maintained coverage of Insmed (NasdaqGS:INSM) with a Overweight recommendation. Analyst Price Forecast Suggests 8.29% Upside
Wed Dec 17, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
INSM Stock trends
INSM Stock performance
INSM Stock analysis
INSM investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.